期刊
CANCER LETTERS
卷 500, 期 -, 页码 253-262出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.11.006
关键词
H19; Long non-coding RNA; Cancer therapeutics; Oncogene; Tumour suppressor
类别
资金
- Singapore Ministry of Health's National Medical Research Council
- National Research Foundation Singapore
- Singapore Ministry of Education under its Research Centres of Excellence initiatives
H19 long non-coding RNA has dual roles in cancer, acting as both an oncogene and a suppressor gene in tumor development. It plays a crucial role in cancer therapy through various mechanisms, including its applications in recombinant vectors, chemoresistance, epigenetic regulation, alteration of tumor microenvironment, and cancer immunotherapy, as well as its relationship with the tumor suppressor gene p53.
H19 long non-coding RNA (lncRNA) has many functions in cancer. Some studies have reported that H19 acts as an oncogene and is involved in cancer progression by activating epithelial-mesenchymal transition (EMT), the cell cycle and angiogenesis via mechanisms like microRNA (miRNA) sponging - the binding to and inhibition of miRNA activity. This makes H19 lncRNA a potential target for cancer therapeutics. However, several conflicting studies have also found that H19 suppresses tumour development. In this review, we shed light on the possible reasons for these conflicting findings. We also summarise the current literature on the applications of H19 lncRNA in cancer therapy in many cancers and explore new avenues for future research. This includes the use of H19 in recombinant vectors, chemoresistance, epigenetic regulation, tumour microenvironment alteration and cancer immunotherapy. The relationship between H19 and the master tumour suppressor gene p53 is also explored. In most studies, H19 knockdown via RNA interference (RNAi) or epigenetic silencing inhibits cancer development. Thus, H19 lncRNA could be a promising target for the development of cancer therapeutics. This warrants further investigations into its translational research to improve cancer therapy outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据